Novavax is trading 5.43% up now at $9.80 after management’s September 10, 2026 strategy update emphasized licensing partnerships, Matrix-M applications, and a path toward profitability by 2028.
- Reports described renewed investor interest in potential oncology applications, but no new cancer-related deal was confirmed.
- Major indexes are up roughly 1%, supporting broader risk appetite.